The identification of these pathways and whether they areoperative before, during, and/or after treatment with HER2-inhibiting drugs might enable individualtherapeutic decisions to be based on tumor biology rather than on basic histopathological data alone[9-23]. This evidence concerns the gene ERBB2 and neoplasm.